BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 19190139)

  • 1. Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer.
    Ma H; Luo J; Press MF; Wang Y; Bernstein L; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):479-85. PubMed ID: 19190139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between mammographic density and basal-like and luminal A breast cancer subtypes.
    Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC
    Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammographic density and hormone receptor expression in breast cancer: the Multiethnic Cohort Study.
    Conroy SM; Pagano I; Kolonel LN; Maskarinec G
    Cancer Epidemiol; 2011 Oct; 35(5):448-52. PubMed ID: 21247819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammographic density in relation to tumor biomarkers, molecular subtypes, and mode of detection in breast cancer.
    Sartor H; Zackrisson S; Elebro K; Hartman L; Borgquist S
    Cancer Causes Control; 2015 Jun; 26(6):931-9. PubMed ID: 25860114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mammographic and pathological features of triple-negative breast cancer].
    Wen SY; Han YW; Ma XM; Zhang J; Cui WJ; Cao XC; Wang X
    Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):291-5. PubMed ID: 22781043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between mammographic density and tumor marker-defined breast cancer subtypes: a case-control study.
    Shin J; Lee JE; Ko HY; Nguyen TL; Nam SJ; Hopper JL; Song YM
    Eur J Cancer Prev; 2018 May; 27(3):239-247. PubMed ID: 28957821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammographic density and estrogen receptor status of breast cancer.
    Ziv E; Tice J; Smith-Bindman R; Shepherd J; Cummings S; Kerlikowske K
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2090-5. PubMed ID: 15598766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.
    John EM; Koo J; Phipps AI; Longacre TA; Kurian AW; Ingles SA; Wu AH; Hines LM
    Breast Cancer Res; 2024 May; 26(1):88. PubMed ID: 38822357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women.
    Yang WT; Dryden M; Broglio K; Gilcrease M; Dawood S; Dempsey PJ; Valero V; Hortobagyi G; Atchley D; Arun B
    Breast Cancer Res Treat; 2008 Oct; 111(3):405-10. PubMed ID: 18026834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
    Ma H; Ursin G; Xu X; Lee E; Togawa K; Malone KE; Marchbanks PA; McDonald JA; Simon MS; Folger SG; Lu Y; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
    Breast Cancer Res; 2018 Jan; 20(1):5. PubMed ID: 29357906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammographic density, response to hormones, and breast cancer risk.
    Boyd NF; Melnichouk O; Martin LJ; Hislop G; Chiarelli AM; Yaffe MJ; Minkin S
    J Clin Oncol; 2011 Aug; 29(22):2985-92. PubMed ID: 21709206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
    Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
    Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Background parenchymal enhancement on breast MRI and mammographic breast density: correlation with tumour characteristics.
    Kim MY; Choi N; Yang JH; Yoo YB; Park KS
    Clin Radiol; 2015 Jul; 70(7):706-10. PubMed ID: 25824280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammographic density and risk of breast cancer by age and tumor characteristics.
    Bertrand KA; Tamimi RM; Scott CG; Jensen MR; Pankratz V; Visscher D; Norman A; Couch F; Shepherd J; Fan B; Chen YY; Ma L; Beck AH; Cummings SR; Kerlikowske K; Vachon CM
    Breast Cancer Res; 2013 Nov; 15(6):R104. PubMed ID: 24188089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics.
    Rice MS; Tamimi RM; Bertrand KA; Scott CG; Jensen MR; Norman AD; Visscher DW; Chen YY; Brandt KR; Couch FJ; Shepherd JA; Fan B; Wu FF; Ma L; Collins LC; Cummings SR; Kerlikowske K; Vachon CM
    Breast Cancer Res Treat; 2018 Jul; 170(1):129-141. PubMed ID: 29502324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.